CD274 and susceptibility to pneumonia measurement: PD-L1 inhibitors showed significant increases in grade 1–5 pneumonitis (RR, 3.25; 95% CI, 1.61–6.57; p < 0.001) and pneumonia (RR, 2.11; 95% CI, 1.20–3.70; p < 0.001).